MYGN Q3 2024 Earnings — Myriad Genetics, Inc. Revenue & Financial Results | Market Cap Arena

MYGNMyriad Genetics, Inc.

$487M

Q3 2024 Earnings

Healthcare Medical - Diagnostics & Research

Income Statement

Revenue

$213M+11.2% YoY

Gross Profit

$150M70.2% margin

Operating Income

-$20M-9.4% margin

Net Income

-$22M-10.4% margin

EPS (Diluted)

$-0.24

QoQ Revenue Growth

+0.9%

Cash Flow

Operating Cash Flow

$700,000

Free Cash Flow

-$6M

Stock-Based Comp.

$12M

Balance Sheet

Total Assets

$1.1B

Total Liabilities

$350M

Stockholders' Equity

$732M

Cash & Equivalents

$100M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$213M	$192M	+11.2%
Gross Profit	$150M	$134M	+11.5%
Operating Income	-$20M	-$60M	+66.7%
Net Income	-$22M	-$61M	+63.9%

Geographic Segments

UNITED STATES

$196M92%

Non-US

$17M8%